Patient groups are essential to understanding the value of medicines, but NICE must improve its disclosure practices for conflicts of interest to ensure credibility and impartiality, write Iva Parvanova, Arianna Gentilini, and colleagues Since its creation, the National Institute for Health and Care Excellence (NICE) has committed to including patient and public perspectives to fully capture the value of medicines.1 For example, in their appraisals, which inform funding recommendations for the English NHS, patient groups and their nominated experts provide testimonies of first hand experiences on how a disease affects them and those around them.2 All contributing parties are required to declare any direct or indirect interests. NICE defines an interest as a situation where there is, or could be perceived to be, an opportunity for a person involved with NICE’s work, or their third party associates, to benefit from NICE’s decisions.3 Relevant interests may be constituted by payments received up to 12 months prior to their involvement with NICE from any commercial organisation that might be affected by NICE’s decisions.3 Reliance on industry funding can undermine the credibility of patient groups …

中文翻译：

---

保护 NICE 免受患者群体的利益冲突

患者群体对于理解药物的价值至关重要，但 NICE 必须改进其利益冲突的披露做法，以确保可信度和公正性，Iva Parvanova、Arianna Gentilini 及其同事写道，自创建以来，国家健康与护理卓越研究所 ( NICE) 致力于纳入患者和公众的观点，以充分体现药物的价值。1 例如，在他们的评估中，为英国 NHS 提供资金建议，患者团体及其指定的专家提供了第一手经验的证词疾病会影响他们和他们周围的人。2 所有出资方都必须申报任何直接或间接利益。NICE 将兴趣定义为存在或可能被认为是的情况，